Native-state proteomics of PV interneurons in wild-type mouse brain
Proteomic biotinylation of native-state PV-INs (PV-CIBOP) was achieved by retro-orbital (RO) delivery of PV-IN-specific enhancer-targeting AAV (PHP.eB-E2-Cre-2A-GFP)33,40,41 into Rosa26TurboID/wt (PV-CIBOP group) or wild-type (WT) mice (Fig. 1A)16. For acute slice electrophysiology of PV-INs, we co-injected (RO) an AAV construct containing a floxed TdTomato sequence to fluorescently-label PV-INs due to non-visualization of GFP in ex vivo slices. After 3 weeks of Cre-recombination and 2 weeks of biotin supplementation8, we performed acute slice current clamp recordings confirming selective targeting and unaltered physiology of fast-spiking PV-INs by PV-CIBOP (Fig. 1A, Supplementary Fig. 1). To assess potential impacts of PV-specific TurboID expression and proteomic biotinylation on PV neuron function and overall local circuit activity, we obtained voltage and current clamp recordings from layer 5 pyramidal neurons and PV interneurons, respectively, in both WT control and PV-CIBOP mice (Supplementary Fig. 1A, B, H). Fast, spontaneous excitatory and inhibitory synaptic events (EPSCs and sIPSCs) were isolated during pyramidal cell recordings (Supplementary Fig. 1B). The amplitude, frequency and kinetic properties of both sEPSCs and sIPSCs were unperturbed in PV-CIBOP brains (Supplementary Fig. 1CâG). These results indicate that PV-CIBOP does not affect basal circuit excitability, synaptic receptor distributions or synaptic properties. In the same slices, neighboring TdTomato+ neurons exhibited fast, non-accommodating firing with narrow action potentials (Supplementary Fig. 1HâJ) and passive properties characteristic of fast-spiking PV-INs (Supplementary Fig. 1KâM). No differences in AP firing, various biophysical features, or passive properties were observed in PV-INs comparing PV-CIBOP with WT controls (Supplementary Fig. 1IâM). Immunohistochemical (IHC) studies from fixed PV-CIBOP cortices showed widespread biotinylation of PV-positive (PVâ+â) and GFP-positive neurons (Fig. 1B, C), in somatic and axo/dendritic compartments of PV-INs (Fig. 1D) without off-target biotinylation or reactive gliosis (Supplementary Fig. 2). Western blots (WB) showed strong biotinylation of a wide array of proteins in PV-CIBOP mice compared to few endogenously biotinylated proteins in WT control lysates (Fig. 1E)8. Using the N-terminal V5 (V5-TurboID) as a surrogate of Cre-mediated TurboID expression, we detected V5 in PV-CIBOP mice but not WT controls (Fig. 1E).
Biotinylated proteins from PV-CIBOP and WT control samples were enriched using streptavidin (SA) beads followed by silver stain and WB (Fig. 1E), confirming enrichment of biotinylated proteins from PV-CIBOP mice, mirroring patterns observed in bulk brain lysates (inputs). Label-free quantitative MS (LFQ-MS) of SA-enriched samples identified a PV-IN proteome of 628 proteins enriched in PV-CIBOP samples as compared to controls (ââ¥â2-fold enriched and unadjusted pââ¤â0.05; 192 proteins â¥2-fold enriched at the FDRââ¤â0.05 threshold) (Fig. 1F, Supplementary Data 1). These included canonical PV-IN proteins, including Kv3 channels (Kcnc1, Kcnc2, Kcnc3; which were expressed at similar levels relative to each other), Gria4, Syt2 and Ank1, while markers of excitatory neurons (Slc17a7), astrocytes (GFAP), microglia (Cst3), oligodendrocytes (Mbp, Plp1) were not enriched (Fig. 1G)33,42,43,44. Gene set enrichment (GSEA) (Fig. 1H) and SynGO (Fig. 1I)45 analyses of the PV-IN proteome showed over-representation of gene ontologies (GO) including synaptodendritic and axonal localization, neurotransmission, vesicle function, synapse organization, ARF-GTPase signaling, growth factor receptor signaling, tauopathy/synucleinopathy, and included pre- and post-synaptic compartments. Some of the most abundant synaptic PV-IN proteins were involved in synaptic vesicle trafficking, fusion and exocytosis and included complexins (Cplx 1-3), synucleins alpha and beta (Snca, Sncb), Bin1 and amphiphysin (Fig. 1J)46. In contrast with bulk brain proteomes (Fig. 1K, L), PV-IN-specific proteomes including GABAergic and Kv3 channels, proteins involved in synaptic vesicle function, endocytic/endosomal pathways, GTPase binding proteins, cytoskeletal proteins (Ank1)43,47 and ribosomal large subunit proteins (Rpl15, Rpl18, Rpl24). Non-PV-IN proteins and glial proteins were preferentially enriched in the bulk brain proteome (Fig. 1L). Using a reference dataset of brain protein half-lives generated by metabolic labeling48, we found that the PV-CIBOP proteome had a similar distribution of short and long half-life proteins (Supplementary Fig. 3). We also verified that the distribution of neuronal soma and axon/synaptic/dendrite-localized proteins in the PV-CIBOP proteome and bulk brain proteome, were similar (Supplementary Fig. 4). These analyses suggest that the PV-CIBOP proteome is indeed representative of the neuronal proteome, rather than being biased by protein turn-over or biased towards specific neuronal compartments. Lastly, we contrasted our PV-IN proteome with reference single cell/nuclear RNAseq PV-IN transcriptomes from mouse brain (Fig. 1M, Supplementary Fig. 5)49, revealing modest concordance between 1,810 mRNA-protein pairs (Spearmanâs Rho=0.27, pâ<â0.001) (Supplementary Data 1).
In summary, our PV-CIBOP studies successfully identified native-state proteomic signatures of PV-INs many of which are not captured by bulk brain proteomics and are discordant with mRNA-level findings.
Proteomic signatures of PV-INs in contrast to Camk2a excitatory neurons reveal molecular signatures associated with vulnerability and cognitive resilience
We contrasted proteomic signatures of PV-INs with Camk2a-positive excitatory neurons using the CIBOP approach in two independent cellular contexts (Fig. 2A)8. Of 1,841 proteins enriched in either PV-CIBOP or Camk2a-CIBOP proteomes (Fig. 2A, Supplementary Data 2), 1,578 were enriched in Camk2a neurons and 1,408 proteins enriched in PV-INs, with 1,135 proteins enriched in both. 245 proteins were highly-enriched (â>â4-fold) in PV-INs (including Kv3 channel proteins) while 163 proteins were highly-enriched in Camk2a neurons (Fig. 2B). Ribosomal, GABA metabolism, ephrin B pathway, clathrin-coated vesicle, transport, cytoskeleton, endoplasmic reticulum, calcium binding, synaptic vesicle exocytosis and Akt/mTOR signaling were over-represented in PV-IN-enriched proteins (Fig. 2C, Supplementary Fig. 6). In contrast, cellular metabolism, fatty acid oxidation, NAD binding, lipid metabolism, proteasome complex, ER-phagosome and mitochondrial terms were over-represented in the Camk2a-CIBOP-enriched proteome (Fig. 2C, Supplementary Fig. 6). Upstream analyses identified potential microRNA (miRNA) regulators of PV-INs and Camk2a neurons, including enrichment of microRNAs 133a and 133b targets in the PV-IN proteome (Supplementary Fig. 6), in agreement with prior miRNA tagging and affinity purification (miRAP)50 studies that identified miRNAs 133a and 133b as highly expressed in PV-INs. Two microRNAs recently identified as predictors of cognitive decline in humans (miR-29a and miR-132), were also predicted to regulate PV-IN proteomic signatures51. These analyses suggest that molecular signatures that define PV-INs may be regulated by distinct sets of miRNAs, some of which have known associations with cognitive decline in humans.
To identify neurodegeneration-relevant proteins in PV-INs, we cross-referenced PV-IN and Camk2a CIBOP proteomic markers with neurodegeneration-associated risk genes from Multi-marker Analysis of GenoMic Annotation (MAGMA) analyses (Fig. 2D, Supplementary Data 2)52,53. We identified 60 PV-IN AD-risk proteins related to synaptic vesicle fusion, docking and recycling (Bin1, Picalm, Dnm2, Ap1g1, Ap2a2, Sgip1), cytoskeleton and microtubules (Ank1, Actb, Tubb2a, Mapt), mitochondria (Mtch2, Ndufs3, Ndufb9, Slc25a11), and SNARE complex (Syn2, Stx1b, Vamp1, Nsf, Stxb1) (Fig. 2E). In comparison, 24 Camk2a neuron-enriched AD-risk proteins were identified, including oxidoreductases (Sdhb, Idh2, Aldh5a1, Etfb and Acadl), serine/threonine kinase Akt3 and TAR DNA binding protein (Tardbp).
We also leveraged data from recent protein-wide association studies of post-mortem human brains from participants in the Religious Orders Study and the Rush Memory and Aging Project (ROSMAP) longitudinal study in which post-mortem brain proteins correlated with rate of cognitive decline, were identified. Using cognitive slope as the outcome, proteins positively correlated with cognitive stability (a positive cognitive slope) represented pro-resilience proteins (nâ=â645). Conversely, proteins that were negatively correlated with cognitive stability (a negative cognitive slope), represented anti-resilience proteins (Nâ=â575)54,55. As compared to the Camk2a-CIBOP proteome, the PV-IN proteome was significantly enriched in pro-resilience proteins, including complexins (Cplx1, Cplx2), Ank1, highly-abundant PV-IN proteins (e.g. Aak1, Cttn, Bin1, Elfn1, Bsn) as well as ribosomal, mitochondrial, GTP binding, synaptic compartment and vesicle fusion proteins (Fig. 2F). While PV-CIBOP is selective to the PV-INs, Camk2a-CIBOP broadly labels several classes of excitatory neurons in the cortex56,57, which limits the ability to detect molecular characteristics of distinct excitatory neuronal sub-classes. Therefore, future studies should apply more selective AAV or transgenic approaches to contrast distinct excitatory neuronal sub-classes.
This evaluation of PV-IN proteomes, in contrast to Camk2a neurons, reveal a generalized molecular phenotype of high translational, synaptic vesicle transport and fusion (neurotransmission), GTP binding and signaling (Akt/mTOR) activities in PV-INs, including many AD-related genetic risk factors and proteins associated with cognitive resilience.
Network analyses of human post-mortem brain proteomes identify unique associations of PV-IN markers with neuropathology and cognitive dysfunction in AD
Supporting evidence for unique vulnerability of PV-INs to neurodegenerative disease pathology in AD may be revealed by analyses of bulk brain proteomes. We interrogated published human post-mortem bulk brain proteomic studies58,59,60,61,62,63,64,65,66,67 which included >500 post-mortem dorsolateral pre-frontal cortex samples (non-disease controls, Asymptomatic AD, and AD with dementia cases) from the ROSMAP and Banner Sun Health cohorts66,67. Over 8,000 proteins quantified in this previous study coalesced into 44 groups of highly co-expressed proteins (modules, annotated as M1-M44)68, some of which were enriched in markers of distinct brain cell types (eg. M1, M5, M10, M33 for neurons, M11 and M12 for astrocytes, M11 and M21 for microglia, M3 for oligodendrocytes), as well as distinct molecular mechanisms (eg. MAPK signaling in module M7)68. These modules also have unique correlations to amyloid burden (CERAD), neurofibrillary tangles (Braak stage), and cognitive function (MMSE or global cognitive function) (Fig. 3A)58,67. Therefore, these modules can be treated as groups of proteins representative of distinct disease mechanisms, some of which may be cell type-specific.
We analyzed this human post-mortem brain proteomic dataset, now using sets of neuron sub-class-specific markers, to identify protein modules that may represent disease mechanisms associated with distinct neuronal classes. We derived 1,040 genes with â¥4-fold enrichment in specific neuronal classes (glutamatergic pyramidal neurons and GABAergic neurons including PV, Sst, VIP subtypes) from the Allen brain single cell/nuclear RNAseq (sc/snRNAseq) atlas (Supplementary Data 3). Pan-excitatory/glutamatergic markers (Camk2a, Slc17a7) were enriched in modules M1, M5, M22, M10 and M4. Pan-inhibitory markers (Gad1-2, Slc32a1) were enriched in modules M33 and M23. Among the inhibitory neuron modules, M33 showed enrichment in PV-IN markers, including Pvalb and Kcnc2 [Kv3.2]), while VIP interneuron markers were enriched in M23 (Fig. 3B). Therefore, M1 (as well as M22, M5, M10 and M4) is enriched in cellular mechanisms of AD in excitatory neurons, while M33 represents AD patho-mechanisms impacting PV-INs. Both pan-excitatory M1 and PV-IN M33 module abundances were lower in AD cases (Fig. 3C, D) and were associated with cognitive function (MMSE and global cognitive function) at last clinical visit prior to death, and negatively associated with severity of dementia and neuropathology (both Aβ and tau) (Fig. 3E, F) although APOE genetic risk was associated with M1, but not M33. This analysis shows that markers of distinct neuronal sub-classes are indeed enriched in specific protein modules, some of which have correlations with clinical and pathological traits and are therefore likely to be pathologically relevant.
We next assessed whether excitatory and inhibitory neuronal signatures obtained from bulk brain proteomes, are associated with rate of cognitive decline (cognitive slope) in longitudinal studies of aging and AD55,69 (Fig. 3G and Supplementary Fig. 7A, B). Using consensus marker lists of cell types from reference human brain single cell/nuclear RNAseq studies, we applied single-sample GSEA (ssGSEA) to proteomic data from 488 post-mortem human dorsolateral pre-frontal cortex (DLPFC) samples from ROSMAP/BANNER studies, to estimate abundances of 19 classes of excitatory and inhibitory neurons, glia and vascular cells (Fig. 3G)1,70,71,72. We also assessed whether protein co-expression modules, some of which are specific to neuronal sub-classes, also correlated with cognitive slope. The associations between different cell type abundances, protein modules and rate of cognitive decline were assessed using a correlation-based adjacency matrix. We found that the PV-IN cell type abundance, modules M33 (enriched in PV-IN markers), M2 and M32 (mitochondria) as well as cognitive slope (cognitive resiliency) were highly inter-correlated (Fig. 3G). In addition to PV-INs, the layer 4 IT neuronal estimate was also positively correlated with cognitive slope (Supplementary Fig. 7A, B). The abundances of these two cell types are therefore linked to cognitive resilience. The association between PV-IN module M33 and cognitive resilience remained significant after adjusting for several co-existent neuropathologies (including amyloid, tau, synuclein), suggesting that the relationship between PV-IN abundance and cognitive resilience may be independent of neuropathology (Supplementary Fig. 7C)55.
Overall, these network-based and correlative analyses of bulk brain proteomic data indirectly suggest that distinct neuronal sub-classes may be differentially impacted in AD pathology, and support the idea that integrity of PV-INs and/or their proteins, may be determinants of cognitive resilience in AD.
Neuron-specific molecular signatures resolve vulnerability of PV neurons to progressive Aβ pathology in the 5xFAD mouse model
The cross-sectional nature and post-mortem sampling of tissue in human post-mortem brain proteomic studies, limit the ability to resolve the impact of aging and disease progression on neuronal protein changes in AD. Since these can be better assessed in disease models, we examined bulk brain proteomes from a mouse model of Aβ pathology. We analyzed TMT-MS data from 43 WT and 43 5xFAD mice (age span 1.8-14.4 mo., 50% male, 50% female), in which over 8,500 proteins were quantified (Fig. 4A, Supplementary Data 4). As expected in 5xFAD mice, age-dependent increase in Aβ pathology was associated with concomitant increase in levels of Apoe, microglial proteins (Trem2, Msn, C1qb) and astrocyte proteins (Gfap) (Fig. 4A). Using 10 and 14 month timepoints, we assessed whether proteomic changes at more established and advanced stages of Aβ pathology in 5xFAD mice, are representative of changes occurring in post-mortem human AD brain using proteomes (control, AD and AsymAD) from the published resource also used in Fig. 368. We observed proteome-wide moderate positive correlations in AD pathological changes occurring across species (Supplementary Fig. 8AâC). Mechanisms involving splicing, proteasome, innate immunity, actin-cytoskeleton and MAPK signaling were increased in human AD and mouse 5xFAD brains (Supplementary Fig. 8D). Conversely, mitochondrial respiration, mitochondrial translation, endocytosis and synaptic signaling were decreased in human AD and mouse 5xFAD brains (Supplementary Fig. 8E).
Based on this evidence of concordance of pathological changes across species based on our and recent proteomics studies73, despite evident inter-species differences between humans and mice, we focused our analysis to canonical transcriptomic markers (Supplementary Data 4) of different neuronal classes49, and identified distinct patterns of change of neuronal proteins with aging and genotype (5xFAD vs WT), as well as biological interaction between aging and genotype. Excitatory neuronal proteins (Camk2a, Slc17a7) showed an age-dependent decrease without an impact of genotype. In contrast, Pvalb and Sst proteins (found in PV-INs and SST GABAergic INs, respectively) increased with age in WT mice, but this trend was significantly blunted by 5xFAD genotype, particularly at 6 months of age (Fig. 4B). Kcnc3, which encodes a Kv3 channel highly expressed by PV-INs, showed an age-dependent decrease in 5xFAD mice while Vip, a marker of VIP-INs, did not show changes related to either age or genotype. We also observed a strong positive correlation between PV-IN proteins (Pvalb and Kcnc3) and myelin proteins (Plp1 and Mbp) (Fig. 4A) indicative of cell-cell interactions between PV-INs and oligodendrocytes74.
Using lists of markers enriched in pan-excitatory, pan-inhibitory neurons, as well as in sub-classes of PV-INs, SST-INs and VIP-INs49, we calculated composite cell-type-specific abundance scores of neuronal classes, to identify age and genotype (5xFAD vs. WT) effects in the bulk proteomic data (Fig. 4C). Pan-excitatory markers decreased with aging, and were minimally higher in abundance in 5xFAD brains as compared to WT, regardless of age. Pan-inhibitory markers also showed an age-dependent decrease in abundance which became more pronounced in 5xFAD mice. Among major IN classes, PV-IN markers showed a gradual increase with age in WT mice, although this was suppressed in 5xFAD brain (Fig. 4B). In contrast, SST-IN and VIP-IN markers were unaffected by genotype (Fig. 4C).
To determine whether PV-IN protein changes in 3-6 month-old 5xFAD mice are related to changes in PV-IN cell numbers or PV-IN proteins75, we performed IHC studies on an independent set of 3 and 6 month-old WT (nâ=â7-8) and 5xFAD (nâ=â7-8) brains, and assessed Pvalb protein levels along with detection of peri-neuronal nets (PNNs) by Wisteria floribunda agglutinin (WFA) in the cortex and subiculum (Fig. 4DâG). PNNs are known to disproportionately encapsulate PV-INs in the brain and are key regulators of PV-IN excitability76,77,78. The number of Pvalb protein-positive neurons in the cortex and subiculum were not impacted by genotype (5xFAD vs WT) at 3 or 6 months of age (Fig. 4D, E, Supplementary Fig. 9) although the proportion of PNN-positive PV-INs was significantly lower in 5xFAD mice (Fig. 4G).
Overall, our analyses of mouse brain proteomic data identify unique age and Aβ-dependent changes that appear to differentially impact neuronal sub-classes, where PV-INs may be selectively vulnerable in early stages of pathology in 5xFAD mice13. Our histological studies suggest that observed proteomic changes in PV-IN proteins in 5xFAD brain is not explained by changes in the absolute numbers of PV-INs79, although the health of PV-INs may be perturbed, as indicated by loss of PNNs around PV-INs in early stages of Aβ pathology and Aβ-induced changes in PV-IN proteins abundances. To better understand the molecular basis for differential vulnerability of PV-INs to AD pathology with spatiotemporal resolution, neuron class-specific native state proteomic investigations using CIBOP are warranted.
Unique molecular signatures of PV-IN proteome in early stages of Aβ pathology in 3 month-old 5xFAD mice
To identify molecular events specifically occurring in PV-INs because of early AD pathology, we applied the PV-CIBOP strategy to achieve PV-IN-specific TurboID expression, biotinylation and fluorescent labeling in WT and 5xFAD mice (Fig. 5A). Three weeks after RO AAV injection and 2 weeks of biotinylation, mice were euthanized at 3 months of age. This early stage of Aβ pathology (i.e., significant Aβ burden with minimal plaque formation restricted to the subiculum) was chosen to capture potentially-modifiable disease mechanisms. IHC confirmed PV-IN-specific biotinylation in the cortex of WT and 5xFAD PV-CIBOP mice (Fig. 5B). Flow cytometry of enzymatically-dissociated cortex7 confirmed equal efficiency of PV-IN targeting across all groups (Fig. 5C). Consistent with early stage of pathology, we observed minimal extracellular Aβ plaque pathology in the subiculum and cortex of 5xFAD mice, while total Aβ42 levels measured by ELISA were substantially increased in 3 month-old 5xFAD mice (Fig. 5D). WBs of cortical lysates showed robust biotinylation and V5 protein signals in all PV-CIBOP mice (Fig. 5E). WB of SA-enriched samples showed enrichment of biotinylated proteins in PV-CIBOP animals compared to controls, regardless of 5xFAD or WT genotype (Fig. 5F, Supplementary Fig. 10A).
LFQ-MS of bulk brain samples (inputs) and SA-enriched (i.e., PV-specific) samples quantified 3,086 proteins and 2,149 proteins respectively (Supplementary Data 5). PCA of bulk proteomes indicated minimal effects of biotinylation on the overall brain proteome (Supplementary Fig. 10B). 1,973 proteins were enriched in the PV-IN proteome from both WT and 5xFAD PV-CIBOP groups as compared to negative control SA-enriched proteomes. Top PV-IN enriched proteins identified in WT/PV-CIBOP tissues in this experiment, including equal levels of enrichment of three Kv3 (3.1, 3.2, 3.3) channel proteins, agreed with findings in the first PV-CIBOP study in Fig. 1 (Supplementary Fig. 10C). PCA resolved differences between PV-CIBOP proteomes from WT and 5xFAD mice (Fig. 5G). We identified 248 differentially enriched proteins (DEPs) in PV-CIBOP proteomes from Turbo-expressing WT and 5xFAD mice, which included 134 proteins that were increased and 114 decreased in 5xFAD PV-INs (Fig. 5H, Supplementary Data 5). In alignment with our physiology studies33, Kv3 protein levels did not vary in young 5xFAD mice (pâ=â0.75, 0.10, 0.25 for Kv3.1, 3.2, and 3.3, respectively; unpaired T-tests). Overall, the PV-IN-specific DEPs in 5xFAD mice had very little overlap with DEPs identified in analyses of bulk brain proteomes from the same mice (Fig. 5I, Supplementary Data 5, Supplementary Fig. 10D). At the level of gene ontologies identified using gene set variation analyses (GSVA), the ontologies differentially enriched in the PV-IN proteome also showed minimal agreement with changes occurring in the bulk proteome (Supplementary Data 5). One example of stark discordance between bulk and PV-IN proteomic changes was the oxidative phosphorylation/aerobic respiration gene set, which was increased in PV-INs but decreased in the bulk proteome (5xFAD vs. WT). In contrast, synaptic proteins were decreased in both bulk and PV-IN proteomes, but the magnitude of this decrease was larger in PV-INs compared to bulk proteomes (Supplementary Data 5). This observed lack of concordance between the effects of 5xFAD genotype on the PV-IN proteome as compared to the bulk brain proteome, suggests unique metabolic/respiratory perturbations in PV-INs, that are most likely diluted in bulk tissue analyses.
Among DEPs identified in the PV-IN proteome, top proteins showing at least 4-fold increase in 5xFAD PV-INs included Cox5a, Dhcr7 and Apeh (Fig. 5J). Cox5a is a Complex IV mitochondrial protein involved in ATP synthesis80. Dhcr7 encodes 7-dehydrocholesterol reductase that catalyzes final rate limiting steps of cholesterol biosynthesis81. Apeh encodes acylaminoacyl-peptide hydrolase that hydrolyses terminal acetylated residues in small acetylated peptides, including degradation of monomeric and oligomeric Aβ82. Synaptic structural proteins including Shank2, Homer1, Map2 were conversely decreased by at least 4-fold in 5xFAD PV-INs (Fig. 5J). GSEA and GSVA identified in PV-IN proteomes showed that mitochondrial function, steroid biosynthesis, small GTPase signaling, and GDP binding were increased in 5xFAD PV-INs while structural/cytoskeletal, synaptic, axonal and dendritic ontologies were decreased in 5xFAD PV-INs (Fig. 5K, L, Supplementary Data 5).
We identified 36 post-synaptic proteins (post-synapse GO:0098794) that showed decreased levels in 5xFAD PV-INs, including structural constituents of the post-synapse (Dlgap1, Homer1, Gphn, Ina, Shank2, Git), enzymes with kinase activity or binding (Ppp1r9b, Bcr, Rtn4, Rheb, Prkar2b, Map2), neurotransmitter receptors (Grin1, Gabra1, Gabbr1), dendritic spine proteins (Grin1, Homer1, Dlgap3, Shank2, Dbn1, Bai1, Tanc2, Ncam1) and ribosomal subunits (Rps19, Rpl10a). Pre-synaptic proteins involved in synaptic vesicle fusion and exocytosis, including Complexins (Cplx1, 2), showed decreased levels in 5xFAD PV-INs (Fig. 5M). Of note, Cplx1 and 2 (but not Cplx3) were more also abundant in PV-INs as compared to Camk2a neurons in our CIBOP studies (Supplementary Fig. 10), in line with a recent proteomic study comparing excitatory and inhibitory synaptosomal fractions83. Several MAGMA-identified AD genetic risk factors also showed differential abundances in 5xFAD PV-INs as compared to WT PV-INs (e.g., decreased- Ppp1r9a, Mapt, Git1; increased- Arf5, Ndufb9, Stx1b (Fig. 5N).
To predict whether changes in the PV-IN synaptic protein landscape would result in detrimental or protective consequences, we cross-referenced the 5xFAD vs. WT PV-IN DEP list against pro-resilience and anti-resilience brain proteins identified in human studies (Supplementary Data 5)36. We found that pro-resilience proteins were over-represented while anti-resilience factors were under-represented in proteins that decreased in 5xFAD PV-INs (Fig. 5O). The pro-resilience proteins which were decreased specifically in PV-INs in early 5xFAD pathology included synaptic structural, synaptic scaffolding, actin/cytoskeleton (Dlgap13/4, Shank2, Homer1, Dbn1, Map1b, Map2, Ank3), ribosome (Rpl10a, Rps19, Mrpl43), mTOR-C1 regulating protein (Rheb), clathrin-dependent endocytic (Aak1, Sgip1, Smap2) and synaptic vesicle fusion/exocytosis/release related proteins (Cplx1, Cplx2, Elfn1, Rab3c, Rims1) (Fig. 5P). Many of these pro-resilience proteins that were decreased in 5xFAD PV-INs (e.g. Cplx1, Cplx2, Elfn1, Rab3c, Rtn4, Dlgap4, Sorbs1, Magi1) were also highly-enriched in PV-INs as compared to Camk2a neurons (Fig. 5P, Supplementary Fig. 10E, F), indicating that the changes in early AD pathology may indeed be related to PV-IN dysfunction.
Overall, these mouse-human integrative analyses indicate that altered levels of PV-IN bouton and dendritic proteins at early stages of Aβ pathology may result in detrimental synaptic or network effects, and thus represent proteomic changes potentially related to cognitive resilience with AD pathology. Thus, we next aimed to understand the functional impact of these PV-specific synaptic proteomic alterations.
Early Aβ pathology impacts PV-pyramidal cell neurotransmission and network activity
We leveraged the âE2â enhancer to express optogenetic actuators in PV-INs (Fig. 6, Supplementary Fig. 11) to measure PV-specific neurotransmission properties, where postsynaptic pyramidal cell recordings represent an integrated response to PV-specific, action potential-evoked neurotransmission. C1V1 (AAV.E2.C1V1) was injected in both WT and 5xFAD mice simultaneously with AAV.Camk2.YFP, which served to confirm accurate viral targeting (Fig. 6A). Acute slices were taken from two separate age cohorts (â~â2 or ~3 months old, 7 or 14 weeks respectively) and voltage clamp recordings were obtained from postsynaptic L5 pyramidal neurons (Fig. 6B). Short (â~â0.2âms) LED-light pulses (590ânm) reliably evoked IPSCs every trial (0.1âHz inter-trial interval) in both WT and 5xFAD recordings with minimal temporal jitter. The amplitude of the first IPSC amplitude was unchanged in both 2- and 3-month-old 5xFAD mice (e.g., 2-month-old WT: 133.5â±â25.90 pA, nâ=â10; 3-month-old 5xFAD: 163.7â±â30.55 pA, nâ=â7; pâ=â0.46, unpaired t-test), suggesting that GABAA receptor availability was similar in the postsynaptic pyramidal cells. As several synaptic vesicle fusion/exocytosis/release related proteins were altered in our 5xFAD PV-IN proteome, we more closely evaluated presynaptic properties (i.e., release probability) of PV-pyramidal synapses.
To examine whether modification of vesicle fusion and association proteins affected release probability and presynaptic dynamics at PV-pyramidal synapses, we measured the paired pulse ratio (PPR)84 and multiple pulse ratio (MPR) of optogenetically-evoked IPSCs at 20âHz using 1.5âmM external Ca2+ (Fig. 6C)85,86. Evaluation of the paired-pulse ratio showed modest depression (PPRâ~â0.9) in WT mice at both age timepoints. In 2-month-old 5xFAD mice, no difference in PPR was observed (Fig. 6D) although synaptic depression did intensify in 5xFAD mice during repetitive stimuli (MPR) at this age (Fig. 6F). However, in 3-month-old 5xFAD mice, a decrease in PPR emerged (Fig. 6D) and this more robust depression was now maintained throughout the stimulus train (Fig. 6F). Together these results show progressive presynaptic dysfunction in PV-pyramidal synapses following early Aβ pathology, consistent with changes in proteins regulating vesicular release probability (Fig. 5). Other mechanisms, such as proteins involved with vesicular docking and replenishment, axonal action potential signaling, and Ca2+ dynamics could also contribute. For example, changes in presynaptic parvalbumin expression may affect short-term plasticity and release probability87. However, we did not observe a change in bulk parvalbumin protein by MS (Fig. 4B) or IHC (Supplementary Fig. 9) at 3 months of age.
We next asked whether the signature of synaptic dysfunction observed in 5xFAD mice could be recapitulated in an independent, adult-onset model of APP/Aβ pathology. We packaged the human APP gene (variant NM_000484.4) into an AAV (AAV.Ef1a.hAPP). This particular APP isoform was chosen as it has been shown to proportionally increase with aging and is associated with increased AD risk88,89. While overexpression of hAPP is expected to produce a significant increase in Aβ90, this approach is distinct in that APP/Ab production is limited to the mature circuit, as in sporadic AD. 5-11 week old PV-Cre mice were co-injected with hAPP-AAV and AAV.DIO.CAG.ChETA for PV-specific optogenetic control Supplementary Fig. 11A. Control mice only received AAV.DIO.CAG.ChETA with saline to normalize overall viral titer across experiments. After 2-3 weeks expression, voltage clamp recordings were obtained from postsynaptic pyramidal neurons using 1.5âmM external Ca2+. Brief (~4âms) LED-light pulses (470ânm) could reliably evoke IPSCs on every trial (0.1âHz inter-trial interval) in both control and hAPP-AAV groups, with minimal temporal jitter Supplementary Fig. 11B,C. Similar to 3-month-old 5xFAD mice, the amplitude of the first PV-PC IPSC was unchanged after hAPP expression (Control: 68.18â±â38.37 pA, nâ=â9; hAPP-AAV: 72.70â±â44.49 pA, nâ=â13; pâ=â0.82, unpaired t-test). Optogenetic stimulation with ChETA also showed modest PV-PC synaptic depression in controls (Fig. 6D vs 6E). While PV-pyramidal synapses are often regarded as strongly depressing, their PPR is often observed as only slightly depressing when external Ca2+ is set at naturalistic levels91,92,93,94, as we found here. Indeed, after elevation of external Ca2+, we found a far more strongly depressing PPR (Supplementary Fig. 11EâG). Furthermore, basal synaptic properties were not attributable to direct Ca2+ entry through the rhodopsin pore locally at the presynapse (Supplementary Fig. 11G). Overall, similar to experiments in 5xFAD, synaptic depression measured via PPR and MPR was again enhanced following adult-onset hAPP-AAV expression (Fig. 6E; Supplementary Fig. 11D). Together these results complement our findings in 5xFAD mice, highlighting the early emergence of presynaptic dysfunction at PV-pyramidal synapses following early Aβ pathology.
Alterations in evoked release in PV-INs may affect basal network excitability by disrupting excitatory/inhibitory balance. Thus, we next examined whether changes in the amplitude and frequency of spontaneous EPSCs and IPSCs were apparent in pyramidal cell recordings from 3 month old 5xFAD mice (Fig. 6G). Interestingly, no changes were observed in either the amplitude or frequency of excitatory and inhibitory spontaneous synaptic events (Fig. 6 H, I) echoing recent work from 3-month-old 5xFAD mice in hippocampal slices, where local circuit behavior and oscillations were also largely resilient to change95. This may be due to several factors, including the relatively low AP frequency of evoked PV firing in the slice. APP/Aβ pathology could also preferentially affect evoked release, but spare stochastic vesicular fusion, as these two processes may be mechanistically independent in the same synapse96.
Potential molecular mechanisms of APP/Aβ pathology on altered neurotransmission
Our optogenetic findings indicate a selective disruption in evoked release at PV-pyramidal synapses. Thus, we next examined relevant SNARE-associated protein changes in 5xFAD mice using PV-CIBOP (Fig. 6J, K). Despite the fact that CIBOP does not explicitly target or isolate synaptic proteins, such as with more formal synaptosomal fractionation approaches, we still identified major SNARE-associated proteins in our proteomic datasets in both WT and 5xFAD mice (Fig. 6L) including Syntaxins, Snap25, Vamp, Synaptotagmins, and Cplx. Among this group of PV-IN SNARE associated proteins, only Cplx1 and 2 were significantly reduced in 3 month old 5xFAD. Interestingly, previous work has found that the loss of Cplx1 and 2 can alter evoked release without affecting spontaneous release, analogous to our findings in 5xFAD above97.
Evidence for extensive mitochondrial protein changes in PV-INs in response to early Aβ pathology
The extensive cell-type-specific proteomic alterations we observed in PV-CIBOP and bulk proteomes thus may be reflective of early homeostatic responses to maintain overall circuit functionality98,99, or potentially related to metabolic stress100, either directly or indirectly relating to Aβ pathology. Therefore, we next sought to explore the extent of changes to mitochondrial proteins and associated metabolic pathways specifically in PV-INs in early stages of Aβ pathology. Of 300 mitochondrial proteins (MitoCarta 3.0) biotinylated in PV-INs101, 30 proteins were increased (e.g. Cox5a, Mpst, Ndufa11, Ckmt1) and 4 proteins that were decreased (Mrpl43, Septin4, Sdhb, Bphl) in 5xFAD compared to WT PV-IN proteomes (Fig. 7A). Proteins involved in complex III, complex IV, complex V, amino acid metabolism and protein homeostasis were differentially enriched in 5xFAD PV-IN proteomes, while mitochondrial central dogma (mitochondria-specific DNA, RNA and translation-related elements), complex II and detoxification related proteins were unaffected (Fig. 7B). In contrast to the PV-IN proteome, only 26 mitochondrial proteins were differentially enriched in the bulk brain proteome, which included only 4 shared DEPs (Fig. 7C). Furthermore, the overall level of concordance between bulk brain and PV-IN mitochondrial protein levels was negligible (R2â=â0.0001). The increase of Cox5a levels in 5xFAD PV-INs but not in the bulk brain tissue was validated by Western Blot, using both bulk brain homogenates and PV-specific enriched proteins (Fig. 7D). In bulk brain MS proteomes, Cox5a showed age-dependent decrease in 5xFAD mice (Fig. 7E), a pattern in stark contrast to increased levels in PV-INs at 3 months. This overall pattern of increased abundances of mitochondrial proteins belonging to most mitochondrial compartments, may represent increased mitochondrial biogenesis to meet increased energy demands needed to sustain PV-IN functionality, particularly in the setting of emerging synaptic defects in early Aβ pathology.
Evidence for decreased mTOR-C1 signaling in PV-INs in early Aβ pathology
The mitochondrial and synaptic derangements occurring in PV-INs in 5xFAD mice suggest that upstream signaling pathways may be dysregulated in PV-INs. Metabolic signaling pathways, including Akt/mTOR, are important regulators of mitochondrial biogenesis and turnover, as well as synaptic function in neurons while several MAPKs (ERK, p38 MAPK, Jnk) impact cell proliferation, synaptic function and survival102,103,104,105. We found that PV-CIBOP labeled 75 proteins involved in Akt/mTOR (eg. Mtor, Rptor, Eif4b) and MAPK (eg. Map2k1, Ras proteins, Pak2, Akt3, Mapk3, Mapk10) signaling pathways (Fig. 8A). Of these, few proteins showed increased (Rhoa, Prkca, Hras, Cacna2d1) and decreased levels (Eif4b, Mapt, Rheb) in 5xFAD PV-INs (Fig. 8B). Interestingly, these differential effects of Aβ pathology were only observed in PV-IN proteomes, and not in the bulk brain proteome with the exception of Rheb, highlighting the specificity of these alterations in PV-INs in early AD pathology (Fig. 8C).
Based on the ability of CIBOP to biotinylate signaling proteins in PV-INs, we performed adapted Luminex assays to detect MAPK (Erk, P38 Mapk and Jnk) and Akt/mTOR signaling phospho-proteins, specifically derived from PV neurons8. In this approach, the biotinylated phospho-protein is immobilized on beads using capture antibodies, and then their biotinylation status is detected by streptavidin-fluorophore, to directly measure PV-IN-derived phospho-proteins from brain homogenates (Fig. 8D, Supplementary Data 5). We found that mTOR signaling (via phosphorylation of mTOR and down-stream target p70 S6K), was decreased in 5xFAD PV-INs while MAPK pathway activation was not altered (Fig. 8E). This pattern of decreased mTOR signaling was consistent with lower levels of Rheb (a direct activator of mTOR-C1 function), higher levels of RhoA (a known inhibitor of Rheb function) and lower levels of Eif4b (involved in translation initiation) in 5xFAD PV-INs (Fig. 8F)106. Collectively, our MS PV-IN CIBOP and adapted Luminex analyses indicate decreased mTOR-C1 activity in 5xFAD PV-INs.
To assess functional relevance of decreased mTOR-C1 in 5xFAD PV-INs, we assessed three composite measures of mTOR-C1 signaling, including autophagy (mTOR-C1 inhibits autophagy)105, translational efficiency/protein degradation (mTOR-C1 increases translational efficiency and decreases protein degradation)107,108 and synaptic plasticity (mTOR-C1 facilitates synaptic plasticity) (Fig. 8F)104. 23 GO-annotated positive regulators of autophagy (GO-0010508) were labeled in PV-INs and collectively, this group showed increased levels in 5xFAD PV-INs (Fig. 8G). Western blot analyses of biotinylated proteins from WT and 5xFAD PV-CIBOP mice found increased LC3-II (relative to LC3-I) in 5xFAD PV-INs as compared to WT PV-INs, consistent with increased autophagy in 5xFAD PV-INs (Fig. 8H). To determine whether decreased mTOR-C1 signaling in 5xFAD PV-INs impacts translational efficiency and/or increased protein degradation, we assessed the relative abundances of long-lived and short-lived proteins in 5xFAD and WT PV-IN proteomes. Using a reference dataset of protein half-life estimates derived from in vivo isotopic labeling studies in adult mice48, we found that DEPs that were increased in 5xFAD PV-INs were biased towards longer-lived proteins, as compared to non-DEPs as well as compared to DEPs with decreased levels in 5xFAD PV-INs (Fig. 8I, Supplementary Data 6). This molecular footprint of relatively-increased abundance of longer-lived proteins in 5xFAD PV-INs is consistent with decreased translational efficiency and/or increased protein degradation in 5xFAD PV-INs. Lastly, we found that proteins involved in regulation of synaptic plasticity (GO-0048167, nâ=â102 proteins) were also decreased in 5xFAD PV-IN proteomes (Fig. 8J), consistent with observed synaptic protein changes and physiological defects presented earlier (Figs. 5,6). These analyses provide congruent lines of evidence for decreased mTOR signaling at various levels of the signaling axis (upstream and downstream of mTOR-C1 function), that are associated with increased autophagic flux, decreased translational efficiency and decreased synaptic plasticity in PV-INs at early stages of Aβ pathology.